Expansion signals OncoLens is rapidly expanding its leadership and advisory footprint with recent board and advisory appointments, signaling potential for upsell into executive sponsorship roles, strategic partnerships, and larger multi-center deployments.

AI driven value The platform emphasizes AI-driven analytics and real world evidence initiatives, presenting opportunities to cross-sell advanced analytics modules, trial matching capabilities, and biomarker testing workflows to cancer centers seeking precision care enhancements.

Revenue growth With reported revenue in the mid tens of millions and a Series A and Series B funding round totaling around $16M in 2024, there is investment appetite for scalable digital health solutions, enabling conversations around expanded licenses, additional modules, and enterprise-wide deployments.

Clinical trial access The OncoLens Research Network and partnerships with industry players create a pathway to propose integrated clinical trial matching and real-world data collaboration services to cancer centers aiming to increase enrollment and improve trial access.

Platform integration Existing tech stack includes Epic Systems and analytics tools, presenting sales opportunities around deeper integrations, data interoperability, and workflow-embedded solutions that align with centers already using Epic for streamlined adoption.